Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Non Operating Investment Income (2021 - 2022)

Immuneering (IMRX) has 2 years of Non Operating Investment Income data on record, last reported at $112353.0 in Q4 2022.

  • For Q4 2022, Non Operating Investment Income changed N/A year-over-year to $112353.0; the TTM value through Dec 2022 reached $18889.0, changed N/A, while the annual FY2022 figure was $18889.0, 138.54% up from the prior year.
  • Non Operating Investment Income reached $112353.0 in Q4 2022 per IMRX's latest filing, up from $39088.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $112353.0 in Q4 2022 and bottomed at -$118386.0 in Q1 2022.